Related Experiment Video

Updated: Jun 5, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

[Medical therapies for hepatocellular carcinoma]

P Merle1, F Mornex

  • 1Service d'hépatogastroentérologie, hôpital de l'Hôtel-Dieu, 1 place de l'Hôpital, Lyon, France. philippe.merle@inserm.fr

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|January 18, 2011
PubMed

Insights

Hepatocellular carcinoma treatments are limited, with standard therapies proving inefficient. Sorafenib, an antiangiogenic drug, offers survival benefits but has restricted indications for advanced liver cancer.

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Medical oncology
  • Cancer therapy development

Context:

  • Limited efficacy of current hepatocellular carcinoma (HCC) treatments.
  • Standard chemotherapies and hormonotherapies show poor outcomes.
  • Need for improved therapeutic options for liver cancer.

Purpose:

  • To review the current landscape of hepatocellular carcinoma (HCC) therapies.
  • To highlight the role and limitations of sorafenib in HCC treatment.
  • To underscore the unmet need for effective liver cancer interventions.

Summary:

  • Hepatocellular carcinoma (HCC) therapies are currently limited and often inefficient.
  • Sorafenib, an antiangiogenic agent, demonstrates significant survival benefits in HCC.
  • Sorafenib's use is restricted to specific advanced HCC patient populations.

Impact:

  • Identifies critical gaps in current hepatocellular carcinoma (HCC) treatment protocols.
  • Emphasizes the need for novel therapeutic strategies for liver cancer.
  • Provides context for future research into more broadly applicable HCC treatments.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...